The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Ranolazine Clonmel 500 mg prolonged-release tablets

Clonmel Healthcare LtdPA0126/356/002

Main Information

Trade NameRanolazine Clonmel 500 mg prolonged-release tablets
Active SubstancesRanolazine
Dosage FormProlonged-release tablet
Licence HolderClonmel Healthcare Ltd
Licence NumberPA0126/356/002

Group Information

ATC CodeC01EB18 ranolazine


License statusAuthorised
Licence Issued29/07/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back